---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-017627"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2025-10-09T23:59:59+00:00"
generated_at: "2026-05-17T04:12:16.520447+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Technologies closes $1.8M registered direct offering of 720K shares at $2.50/share

## Summary
- Issued 720,000 shares of common stock at $2.50/share; gross proceeds of ~$1.8M before fees.
- Net proceeds to fund working capital, support growing sales of CyPath® Lung, and general corporate purposes.
- Officers and directors subject to 60-day lock-up; company restricted from further equity issuance until Nov 14, 2025.
- WallachBeth Capital acted as sole placement agent; received 8.0% cash fee plus up to $75K expenses.
- Offering closed on October 9, 2025; shares sold under effective shelf registration statement on Form S-3.

## SEC filing metadata
- accession: 0001493152-25-017627
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2025-10-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315225017627/0001493152-25-017627-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315225017627/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-017627
- JSON: https://secwatch.observer/filing/0001493152-25-017627.json
- Plain text: https://secwatch.observer/filing/0001493152-25-017627.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.